Investor Type | Firm |
Industries | BioTech • Life Science • Nanotechnology • Oncology |
Investing | United States |
Methuselah Fund is a venture capital firm that focuses on accelerating breakthroughs in the longevity field with the ambition to extend the healthy human lifespan. Their mission is encapsulated in the aspiration to make 90 the new 50 by the year 2030. By driving capital into cutting-edge ventures that align with their mission, Methuselah Fund leverages a strategic approach to enable access to advanced life-extending science and technologies for everyone. Their investment thesis revolves around backing companies which contribute to one or more of their anti-aging strategies, which include the creation of new organs, bones, and vasculature; restoration of the body's informational integrity and accurate replication; fortification and rebuilding of bodily walls; safe removal of senescent cells and other destructive biological structures; replenishment of stem cells and immune system antibodies; enhancement of the circulatory system's competence; as well as advancing the capacity for joy through rejuvenated senses and athletic competence.The fund is an embodiment of strategies that emerge from elegantly simple ideas with potential mass influence, led by the DNA of Methuselah Foundation—known for its 16-year history of advancements in extending human life. Methuselah Fund has notably direct access to key players in the longevity space and their operations demonstrate proven capacities to aid their portfolio companies in thriving. Their portfolio showcases a diverse array of leading ventures including Leucadia Therapeutics, Oisín Biotechnologies, Turn Biotechnologies, OncoSenX, Volumetric, Viscient, and X-Therma, each bringing innovative solutions that range from addressing Alzheimer's disease to 3D printing organs, fighting cancer, and protecting tissues from ice damage. Their team is robust with experienced and talented advisors, entrepreneurs, and scientists such as David Gobel, Sergio Ruiz, Keith Murphy, Matthew Scholz, Gary Hudson, Ely Kahn, Aubrey de Grey, and others who bring multifaceted expertise and insights to the table.The ethical and legal framework guiding Methuselah Fund's practices is outlined on their website, which emphasizes investor protection, privacy, and data security. Overall, Methuselah Fund is dedicated to not just the financial viability of their investments but the actualization of a future where longevity science substantially shifts the paradigm of human health and lifespan.